{"success":true,"data":{"pressRelease":{"id":"40006","rtpr_id":"nBw8Hq7dJa","ticker":"AUNA","exchange":"NYSE","all_tickers":["AUNA","GZ4"],"title":"Auna Announces 1Q26 Financial Results","author":"Business Wire","published_at":"2026-05-19T21:50:00.122Z","article_body":"Auna Announces 1Q26 Financial Results\n\nStrong top-line growth and cash flow performance;\n\nConsolidated Adjusted EBITDA impacted by revenue adjustments;\n\nMexico volumes and revenues growing rapidly, with Segment Adjusted EBITDA\nincreasing 19% QoQ\n\nAuna (NYSE: AUNA) (“Auna” or the “Company”), a leading healthcare\nplatform in Latin America with operations in Mexico, Peru, and Colombia,\nannounced today financial results for the first quarter ended March 31, 2026\n(“first quarter 2026” or “1Q26”). Financial results are expressed in\nPeruvian Soles (“S/” or “PEN” or “Soles”) and are presented in\naccordance with International Financial Reporting Standards (“IFRS”),\nunless otherwise noted.\n\n1Q’26 Consolidated Highlights\n\n\n * Revenue increased 10% FXN, or 13% YoY on a reported basis, to S/1,178 million\n\n * Mexico Revenue increased 15% YoY on a reported basis, to S/ 279 million\n\n * Adjusted EBITDA was S/217 million, a decrease of 2% YoY\n\n * Adjusted EBITDA Margin of 18.4%, down 2.9 p.p. YoY from 21.4% in 1Q25\n\n * Operating Cash Flow and Free Cash Flow increased 48% YoY and 2.6x YoY,\nrespectively\n\n * Leverage Ratio was stable at 3.7x\n\n * Oncology MLR decreased 2.0 p.p. YoY to 49.6%\n\n * Number of surgeries increased 4.4% YoY to 21,610\n\n * Number of days hospitalized increased 2.9% YoY to 132,266\n\nMessage from Auna’s Executive Chairman and President\n\nAuna began 2026 with strong commercial momentum across all three of our\nmarkets. First quarter revenues grew 10% FXN, reflecting the impact of the\nstrategic and structural decisions implemented throughout 2025 and further\nvalidating the strength of our integrated platform. The AunaWay model\ncontinues driving sustainable growth across our markets, with positive\nunderlying operating trends, despite short-term Adjusted EBITDA impacts in\nPeru and Mexico.\n\nIn Peru, our integrated healthcare model continued to perform well at scale,\ndelivering solid top-line growth of 9% in local currency, with strong volume\nincreases across hospitals, emergency services, and oncology. Oncosalud\nmaintained its growth trajectory, adding new members and securing a group\npolicy for the nation’s judiciary — a new and prestigious institutional\nrelationship representing nearly 20,000 lives, and contributing to a total of\n1.4 million Oncosalud members. While the underlying business dynamic and\nmargin contributions remain stable in Peru, Adjusted EBITDA was impacted in\nthe healthcare services business by delays in pharmacy rebates and revenue\nadjustments related to certain payors. Oncosalud's MLR of 49.6% in the quarter\nis consistent with our pricing and MLR management discipline.\n\nIn Mexico, our healthcare network continues showing strong signs of recovery\nand our oncology and high-complexity footprint is growing. Sequential Adjusted\nEBITDA increased 19% from 4Q25 and margins improved 3.5 p.p. The healthcare\nnetwork delivered 8% year-over-year revenue growth in local currency and the\nMonterrey operational initiatives gained further traction. Patient volumes\nincreased 13% quarter-over-quarter, as our growing relationships with payors\nand our commitment to contain costs for them, while improving patient\nexperiences and medical resolutions are producing higher revenues across\nservice lines. Our oncology business grew 32% from 4Q25 representing 11% of\nMexico network revenues, up from 4% one year ago. These trends reflect the\nimpact of the growth initiatives implemented under our new Monterrey\nleadership team and are delivering clear results.\n\nIn Colombia, revenue grew 14% in local currency, PGP risk-sharing contracts\nnow represent 21% of total revenues, and revenues from intervened payors have\ndecreased from 19% to 14% versus the first quarter of 2025, reflecting\nsignificant progress in diversifying our payor mix. Adjusted EBITDA grew 7%,\ndemonstrating that disciplined growth and revenue diversification can advance\nin tandem. Overall, Colombia continues to demonstrate the resilience and\ncash-generating capacity of Auna’s integrated model.\n\nOur cash flow performance was a standout in the quarter and a key proof point\nof our model’s strength. Operating Cash Flow grew 48% year-over-year while\nOrganic Free Cash Flow grew 2.6x, supported by consistent working capital\ndiscipline and supplier financing initiatives across all three geographies.\nThis performance validates the underlying robustness of Auna's regional\nplatform and keeps us on track to reach our medium-term leverage target of\nbelow 3.0x. The Leverage Ratio of 3.7x at quarter end remained stable but was\nimpacted by non-cash FX effects.\n\nWe enter the remainder of 2026 with improving trends across all three markets\nand a clear line of sight to achieve our annual targets. We are reaffirming\nour full-year revenue and Adjusted EBITDA guidance supported by our revenue\ngrowth and cash flow momentum, and Mexico’s improving trends, revenue\nnormalization in Peru, and the performance of Colombia. Our Adjusted EBITDA\nguidance contemplated a softer first half of the year, with limited growth\nexpected in the first and second quarters. Against that backdrop, our first\nquarter performance gives us confidence in our ability to deliver our\nfull-year Adjusted EBITDA range. Auna's integrated healthcare model and the\nstructural market opportunity that remains in our three markets position us to\ndeliver on 2026 and build toward higher levels of sustained growth and\nprofitability.\n\nOverview of 1Q26 Consolidated Results\n\nRevenues in 1Q26 increased 10% FXN and 13% YoY on a reported basis to S/1,178\nmillion, with revenues in local currency (“LC”) increasing across all\nsegments: 8% in Mexico, 9% in Peru and 14% in Colombia. The Healthcare network\nin Mexico delivered higher volumes as a result of improved tier\nclassifications with payors, better ISSSTELEON pricing for high complexity\nservices and increased packages and out-of-pocket revenues. In Peru, Oncosalud\nincreased revenues from pricing adjustments and additional B2B memberships,\nwhile the healthcare network experienced higher volumes from commercial\ninitiatives and higher conversion rates in surgeries. Colombia increased\nvolumes across its services, having successfully implemented risk sharing\nmodels to diversify its payor mix away from intervened payors.\n\nAdjusted EBITDA in 1Q26 decreased 5% FXN, or 2% YoY on a reported basis, to\nS/217 million, with an Adjusted EBITDA Margin of 18.4%. In LC, Segment\nAdjusted EBITDA decreased 14% in Mexico and 3% in Peru, while increasing 7% in\nColombia YoY. In Mexico, Segment Adjusted EBITDA decreased versus 1Q25, mainly\ndue to a lower contribution margin from the current mix of services and\nspecialties, as well as higher SG&A expenses related to talent investments\nthat impacted payroll. On a sequential basis, however, Segment Adjusted EBITDA\ngrew a healthy 19% versus 4Q25, driving a 3.5 p.p. increase in Segment\nAdjusted EBITDA Margin. Consolidated Peru Adjusted EBITDA was impacted by\ndelayed rebate benefits and revenue adjustments. In Colombia, Segment Adjusted\nEBITDA increased, sustained by a strong top line, partially offset by lower\nmargins from a higher proportion of PGP contracts that prioritize cashflow\nover revenues.\n\nReported results were impacted by foreign exchange fluctuations, specifically,\na 7% appreciation of the Mexican Peso (“MXN”) and a 4% appreciation of the\nColombian Peso (“COP”) against the PEN.\n\nNet finance costs for 1Q26 were S/141 million, compared to S/80 million in\n1Q25. Excluding foreign exchange effects, net finance costs totaled S/115\nmillion in 1Q26, compared to S/118 million in 1Q25, reflecting a YoY decrease\nof S/3 million, or 3%. When also excluding the non-cash impact related to the\nfuture purchase obligation for IMAT Oncomedica, which began affecting finance\nexpense in 3Q25, net finance costs decreased by S/5 million. The increase in\nreported net finance costs was primarily driven by a non-cash FX loss of S/26\nmillion, mainly due to the depreciation of the Peruvian Sol below the\nprotection range of Auna’s new hedging structure, compared to a non-cash\ngain of S/37 million in 1Q25. At the end of 2025, we reset our call-spread\nlevels to better align them with the prevailing USD/PEN exchange rate and\nreduce future P&L volatility. As a result, the loss recorded in 1Q26 would\nhave been larger had the reset not been completed in 2025.\n\nNet Income for 1Q26 was S/9 million compared to S/38 million in 1Q25. The\ndecline was primarily driven by the negative non-cash FX impact on net finance\ncosts in 1Q26, compared to a positive effect in the prior-year period. On a\nper-share basis, Net Income was S/0.09, based on a weighted average of\n74,238,842 basic and diluted shares.\n\nAdjusted Net Income for 1Q26 was S/16 million, compared to S/55 million in\n1Q25. The decline reflects the same FX-driven impact on net finance costs,\nwith underlying operating performance remaining consistent with the trends\ndescribed above. On a per-share basis, Adjusted Net Income was S/0.18, based\non a weighted average of 74,238,842 basic and diluted shares.\n\nFor a full version of AUNA’s First Quarter 2026 Earnings Release, please\nvisit:\n\nhttps://aunainvestors.com/English/financial-information/quarterly-results/\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Faunainvestors.com%2FEnglish%2Ffinancial-information%2Fquarterly-results%2F&esheet=54538861&newsitemid=20260519356955&lan=en-US&anchor=https%3A%2F%2Faunainvestors.com%2FEnglish%2Ffinancial-information%2Fquarterly-results%2F&index=1&md5=f9ada1e159628dc9d29126e0a3865a38)\n\nConference Call Details\n\nWhen: 8:00 a.m. Eastern time, May 20, 2026\n\nWho: Mr. Suso Zamora, Executive Chairman of the Board and President; Mrs.\nGisele Remy, Chief Financial Officer and Executive Vice President; Mr. Lorenzo\nMassart, Executive Vice President of Strategy and Equity Capital Markets.\n\nDial-in: +1 888 596 4144 (U.S. domestic), +1 646 968 2525 (International)\n\nPasscode: 3884034\n\nTo access Auna′s financial results call via telephone, callers need to press\n# to be connected to an operator.\n\nWebcast: click here\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fevents.q4inc.com%2Fattendee%2F288424677&esheet=54538861&newsitemid=20260519356955&lan=en-US&anchor=click+here&index=2&md5=1664e4d595a52a19b5defcd6ddd0d139)\n\nAbout AUNA\n\nAuna is a leading healthcare platform in Latin America with operations in\nMexico, Peru, and Colombia, prioritizing prevention and concentrating on\nhigh-complexity diseases that contribute the most to healthcare expenditures.\nOur mission is to transform healthcare by providing access to a highly\nintegrated healthcare offering in the underpenetrated markets of\nSpanish-Speaking Americas. Founded in 1989, Auna has built one of Latin\nAmerica′s largest modern healthcare platforms that consists of a\nhorizontally integrated network of healthcare facilities and a vertically\nintegrated portfolio of oncological plans and selected general healthcare\nplans. As of March 31, 2026, Auna’s network included 31 healthcare network\nfacilities, consisting of hospitals, outpatient, prevention and wellness\nfacilities with a total of 2,337 beds, and 1.4 million healthcare plans.\n\nFor more information visit www.aunainvestors.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.aunainvestors.com&esheet=54538861&newsitemid=20260519356955&lan=en-US&anchor=www.aunainvestors.com&index=3&md5=04d81b1016aa0b1144e891c9da9e4923)\n.\n\nSafe Harbor Statement\n\nThis press release contains forward-looking statements. Forward-looking\nstatements convey our current expectations or forecasts of future events.\nThese statements involve known and unknown risks, uncertainties and other\nfactors which may cause our actual results, performance or achievements to\ndiffer materially from the forward-looking statements that we make.\nForward-looking statements typically are identified by words or phrases such\nas “may,” “will,” “expect,” “anticipate,” “aim,”\n“estimate,” “intend,” “project,” “plan,” “believe,”\n“potential,” “continue,” “is/are likely to,” or other similar\nexpressions. Forward-looking statements that appear in a number of places in\nthis press release include, but are not limited to, statements regarding the\nintent, belief or current expectations, regarding various matters, including,\nour target Leverage Ratio, the results of the key initiatives we are\nimplementing in Mexico, Colombia and Peru, the execution of our strategic\nplan, including the recovery of our growth levels and the roll-out of the\nAunaWay in Mexico, our planned investments, our revenue and Adjusted EBITDA\nguidance, our expectation for revenue and EBITDA growth and the creation of\nfurther growth and sustainable value for all stakeholders. Any or all of our\nforward-looking statements in this press release may turn out to be\ninaccurate. Our actual results could differ materially from those contained in\nforward-looking statements due to a number of factors.\n\nThe forward-looking statements in this press release represent our\nexpectations and forecasts as of the date of this press release. Except as\nrequired by law, we undertake no obligation to update or revise publicly any\nforward-looking statements, whether as a result of new information, future\nevents or otherwise, after the date of this press release. For a discussion of\nthe risks facing the Company which could affect whether these forward-looking\nstatements are realized, see our Form 20-F filing with the U.S. Securities and\nExchange Commission (the “SEC”).\n\nFinancial Guidance Disclaimer\n\nAuna′s guidance is based on management’s current performance outlook and\nexpected macroeconomic and regulatory conditions in the three countries where\nthe Company operates. Any changes in these conditions could have an impact on\nthe guidance provided.\n\nAuna’s financial guidance reflects management’s current assumptions\nregarding numerous evolving factors that are difficult to accurately predict,\nincluding those discussed in the Risk Factors set forth in the Company’s\nForm 20-F filed with the SEC. Reconciliations of forward-looking non-IFRS\nmeasures, specifically the Leverage Ratio and Adjusted EBITDA guidance, to the\nrelevant forward-looking IFRS measures are not being provided, as the Company\ndoes not currently have sufficient data to accurately estimate the variables\nand individual adjustments for such guidance and reconciliations. Due to this\nuncertainty, the Company cannot reconcile projected Adjusted EBITDA to\nprojected net income without unreasonable effort. The financial guidance\nconstitutes forward-looking statements. For more information, see the\n“Forward-Looking Statements” section in this release.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260519356955/en/\n(https://www.businesswire.com/news/home/20260519356955/en/)\n\nIR Contact \n\nEmail: contact@aunainvestors.com (mailto:contact@aunainvestors.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw8Hq7dJa","title":"Auna Announces 1Q26 Financial Results","author":"Business Wire","ticker":"AUNA","created":"2026-05-19T21:50:00.122Z","tickers":["AUNA","GZ4"],"exchange":"NYSE","article_body":"Auna Announces 1Q26 Financial Results\n\nStrong top-line growth and cash flow performance;\n\nConsolidated Adjusted EBITDA impacted by revenue adjustments;\n\nMexico volumes and revenues growing rapidly, with Segment Adjusted EBITDA\nincreasing 19% QoQ\n\nAuna (NYSE: AUNA) (“Auna” or the “Company”), a leading healthcare\nplatform in Latin America with operations in Mexico, Peru, and Colombia,\nannounced today financial results for the first quarter ended March 31, 2026\n(“first quarter 2026” or “1Q26”). Financial results are expressed in\nPeruvian Soles (“S/” or “PEN” or “Soles”) and are presented in\naccordance with International Financial Reporting Standards (“IFRS”),\nunless otherwise noted.\n\n1Q’26 Consolidated Highlights\n\n\n * Revenue increased 10% FXN, or 13% YoY on a reported basis, to S/1,178 million\n\n * Mexico Revenue increased 15% YoY on a reported basis, to S/ 279 million\n\n * Adjusted EBITDA was S/217 million, a decrease of 2% YoY\n\n * Adjusted EBITDA Margin of 18.4%, down 2.9 p.p. YoY from 21.4% in 1Q25\n\n * Operating Cash Flow and Free Cash Flow increased 48% YoY and 2.6x YoY,\nrespectively\n\n * Leverage Ratio was stable at 3.7x\n\n * Oncology MLR decreased 2.0 p.p. YoY to 49.6%\n\n * Number of surgeries increased 4.4% YoY to 21,610\n\n * Number of days hospitalized increased 2.9% YoY to 132,266\n\nMessage from Auna’s Executive Chairman and President\n\nAuna began 2026 with strong commercial momentum across all three of our\nmarkets. First quarter revenues grew 10% FXN, reflecting the impact of the\nstrategic and structural decisions implemented throughout 2025 and further\nvalidating the strength of our integrated platform. The AunaWay model\ncontinues driving sustainable growth across our markets, with positive\nunderlying operating trends, despite short-term Adjusted EBITDA impacts in\nPeru and Mexico.\n\nIn Peru, our integrated healthcare model continued to perform well at scale,\ndelivering solid top-line growth of 9% in local currency, with strong volume\nincreases across hospitals, emergency services, and oncology. Oncosalud\nmaintained its growth trajectory, adding new members and securing a group\npolicy for the nation’s judiciary — a new and prestigious institutional\nrelationship representing nearly 20,000 lives, and contributing to a total of\n1.4 million Oncosalud members. While the underlying business dynamic and\nmargin contributions remain stable in Peru, Adjusted EBITDA was impacted in\nthe healthcare services business by delays in pharmacy rebates and revenue\nadjustments related to certain payors. Oncosalud's MLR of 49.6% in the quarter\nis consistent with our pricing and MLR management discipline.\n\nIn Mexico, our healthcare network continues showing strong signs of recovery\nand our oncology and high-complexity footprint is growing. Sequential Adjusted\nEBITDA increased 19% from 4Q25 and margins improved 3.5 p.p. The healthcare\nnetwork delivered 8% year-over-year revenue growth in local currency and the\nMonterrey operational initiatives gained further traction. Patient volumes\nincreased 13% quarter-over-quarter, as our growing relationships with payors\nand our commitment to contain costs for them, while improving patient\nexperiences and medical resolutions are producing higher revenues across\nservice lines. Our oncology business grew 32% from 4Q25 representing 11% of\nMexico network revenues, up from 4% one year ago. These trends reflect the\nimpact of the growth initiatives implemented under our new Monterrey\nleadership team and are delivering clear results.\n\nIn Colombia, revenue grew 14% in local currency, PGP risk-sharing contracts\nnow represent 21% of total revenues, and revenues from intervened payors have\ndecreased from 19% to 14% versus the first quarter of 2025, reflecting\nsignificant progress in diversifying our payor mix. Adjusted EBITDA grew 7%,\ndemonstrating that disciplined growth and revenue diversification can advance\nin tandem. Overall, Colombia continues to demonstrate the resilience and\ncash-generating capacity of Auna’s integrated model.\n\nOur cash flow performance was a standout in the quarter and a key proof point\nof our model’s strength. Operating Cash Flow grew 48% year-over-year while\nOrganic Free Cash Flow grew 2.6x, supported by consistent working capital\ndiscipline and supplier financing initiatives across all three geographies.\nThis performance validates the underlying robustness of Auna's regional\nplatform and keeps us on track to reach our medium-term leverage target of\nbelow 3.0x. The Leverage Ratio of 3.7x at quarter end remained stable but was\nimpacted by non-cash FX effects.\n\nWe enter the remainder of 2026 with improving trends across all three markets\nand a clear line of sight to achieve our annual targets. We are reaffirming\nour full-year revenue and Adjusted EBITDA guidance supported by our revenue\ngrowth and cash flow momentum, and Mexico’s improving trends, revenue\nnormalization in Peru, and the performance of Colombia. Our Adjusted EBITDA\nguidance contemplated a softer first half of the year, with limited growth\nexpected in the first and second quarters. Against that backdrop, our first\nquarter performance gives us confidence in our ability to deliver our\nfull-year Adjusted EBITDA range. Auna's integrated healthcare model and the\nstructural market opportunity that remains in our three markets position us to\ndeliver on 2026 and build toward higher levels of sustained growth and\nprofitability.\n\nOverview of 1Q26 Consolidated Results\n\nRevenues in 1Q26 increased 10% FXN and 13% YoY on a reported basis to S/1,178\nmillion, with revenues in local currency (“LC”) increasing across all\nsegments: 8% in Mexico, 9% in Peru and 14% in Colombia. The Healthcare network\nin Mexico delivered higher volumes as a result of improved tier\nclassifications with payors, better ISSSTELEON pricing for high complexity\nservices and increased packages and out-of-pocket revenues. In Peru, Oncosalud\nincreased revenues from pricing adjustments and additional B2B memberships,\nwhile the healthcare network experienced higher volumes from commercial\ninitiatives and higher conversion rates in surgeries. Colombia increased\nvolumes across its services, having successfully implemented risk sharing\nmodels to diversify its payor mix away from intervened payors.\n\nAdjusted EBITDA in 1Q26 decreased 5% FXN, or 2% YoY on a reported basis, to\nS/217 million, with an Adjusted EBITDA Margin of 18.4%. In LC, Segment\nAdjusted EBITDA decreased 14% in Mexico and 3% in Peru, while increasing 7% in\nColombia YoY. In Mexico, Segment Adjusted EBITDA decreased versus 1Q25, mainly\ndue to a lower contribution margin from the current mix of services and\nspecialties, as well as higher SG&A expenses related to talent investments\nthat impacted payroll. On a sequential basis, however, Segment Adjusted EBITDA\ngrew a healthy 19% versus 4Q25, driving a 3.5 p.p. increase in Segment\nAdjusted EBITDA Margin. Consolidated Peru Adjusted EBITDA was impacted by\ndelayed rebate benefits and revenue adjustments. In Colombia, Segment Adjusted\nEBITDA increased, sustained by a strong top line, partially offset by lower\nmargins from a higher proportion of PGP contracts that prioritize cashflow\nover revenues.\n\nReported results were impacted by foreign exchange fluctuations, specifically,\na 7% appreciation of the Mexican Peso (“MXN”) and a 4% appreciation of the\nColombian Peso (“COP”) against the PEN.\n\nNet finance costs for 1Q26 were S/141 million, compared to S/80 million in\n1Q25. Excluding foreign exchange effects, net finance costs totaled S/115\nmillion in 1Q26, compared to S/118 million in 1Q25, reflecting a YoY decrease\nof S/3 million, or 3%. When also excluding the non-cash impact related to the\nfuture purchase obligation for IMAT Oncomedica, which began affecting finance\nexpense in 3Q25, net finance costs decreased by S/5 million. The increase in\nreported net finance costs was primarily driven by a non-cash FX loss of S/26\nmillion, mainly due to the depreciation of the Peruvian Sol below the\nprotection range of Auna’s new hedging structure, compared to a non-cash\ngain of S/37 million in 1Q25. At the end of 2025, we reset our call-spread\nlevels to better align them with the prevailing USD/PEN exchange rate and\nreduce future P&L volatility. As a result, the loss recorded in 1Q26 would\nhave been larger had the reset not been completed in 2025.\n\nNet Income for 1Q26 was S/9 million compared to S/38 million in 1Q25. The\ndecline was primarily driven by the negative non-cash FX impact on net finance\ncosts in 1Q26, compared to a positive effect in the prior-year period. On a\nper-share basis, Net Income was S/0.09, based on a weighted average of\n74,238,842 basic and diluted shares.\n\nAdjusted Net Income for 1Q26 was S/16 million, compared to S/55 million in\n1Q25. The decline reflects the same FX-driven impact on net finance costs,\nwith underlying operating performance remaining consistent with the trends\ndescribed above. On a per-share basis, Adjusted Net Income was S/0.18, based\non a weighted average of 74,238,842 basic and diluted shares.\n\nFor a full version of AUNA’s First Quarter 2026 Earnings Release, please\nvisit:\n\nhttps://aunainvestors.com/English/financial-information/quarterly-results/\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Faunainvestors.com%2FEnglish%2Ffinancial-information%2Fquarterly-results%2F&esheet=54538861&newsitemid=20260519356955&lan=en-US&anchor=https%3A%2F%2Faunainvestors.com%2FEnglish%2Ffinancial-information%2Fquarterly-results%2F&index=1&md5=f9ada1e159628dc9d29126e0a3865a38)\n\nConference Call Details\n\nWhen: 8:00 a.m. Eastern time, May 20, 2026\n\nWho: Mr. Suso Zamora, Executive Chairman of the Board and President; Mrs.\nGisele Remy, Chief Financial Officer and Executive Vice President; Mr. Lorenzo\nMassart, Executive Vice President of Strategy and Equity Capital Markets.\n\nDial-in: +1 888 596 4144 (U.S. domestic), +1 646 968 2525 (International)\n\nPasscode: 3884034\n\nTo access Auna′s financial results call via telephone, callers need to press\n# to be connected to an operator.\n\nWebcast: click here\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fevents.q4inc.com%2Fattendee%2F288424677&esheet=54538861&newsitemid=20260519356955&lan=en-US&anchor=click+here&index=2&md5=1664e4d595a52a19b5defcd6ddd0d139)\n\nAbout AUNA\n\nAuna is a leading healthcare platform in Latin America with operations in\nMexico, Peru, and Colombia, prioritizing prevention and concentrating on\nhigh-complexity diseases that contribute the most to healthcare expenditures.\nOur mission is to transform healthcare by providing access to a highly\nintegrated healthcare offering in the underpenetrated markets of\nSpanish-Speaking Americas. Founded in 1989, Auna has built one of Latin\nAmerica′s largest modern healthcare platforms that consists of a\nhorizontally integrated network of healthcare facilities and a vertically\nintegrated portfolio of oncological plans and selected general healthcare\nplans. As of March 31, 2026, Auna’s network included 31 healthcare network\nfacilities, consisting of hospitals, outpatient, prevention and wellness\nfacilities with a total of 2,337 beds, and 1.4 million healthcare plans.\n\nFor more information visit www.aunainvestors.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.aunainvestors.com&esheet=54538861&newsitemid=20260519356955&lan=en-US&anchor=www.aunainvestors.com&index=3&md5=04d81b1016aa0b1144e891c9da9e4923)\n.\n\nSafe Harbor Statement\n\nThis press release contains forward-looking statements. Forward-looking\nstatements convey our current expectations or forecasts of future events.\nThese statements involve known and unknown risks, uncertainties and other\nfactors which may cause our actual results, performance or achievements to\ndiffer materially from the forward-looking statements that we make.\nForward-looking statements typically are identified by words or phrases such\nas “may,” “will,” “expect,” “anticipate,” “aim,”\n“estimate,” “intend,” “project,” “plan,” “believe,”\n“potential,” “continue,” “is/are likely to,” or other similar\nexpressions. Forward-looking statements that appear in a number of places in\nthis press release include, but are not limited to, statements regarding the\nintent, belief or current expectations, regarding various matters, including,\nour target Leverage Ratio, the results of the key initiatives we are\nimplementing in Mexico, Colombia and Peru, the execution of our strategic\nplan, including the recovery of our growth levels and the roll-out of the\nAunaWay in Mexico, our planned investments, our revenue and Adjusted EBITDA\nguidance, our expectation for revenue and EBITDA growth and the creation of\nfurther growth and sustainable value for all stakeholders. Any or all of our\nforward-looking statements in this press release may turn out to be\ninaccurate. Our actual results could differ materially from those contained in\nforward-looking statements due to a number of factors.\n\nThe forward-looking statements in this press release represent our\nexpectations and forecasts as of the date of this press release. Except as\nrequired by law, we undertake no obligation to update or revise publicly any\nforward-looking statements, whether as a result of new information, future\nevents or otherwise, after the date of this press release. For a discussion of\nthe risks facing the Company which could affect whether these forward-looking\nstatements are realized, see our Form 20-F filing with the U.S. Securities and\nExchange Commission (the “SEC”).\n\nFinancial Guidance Disclaimer\n\nAuna′s guidance is based on management’s current performance outlook and\nexpected macroeconomic and regulatory conditions in the three countries where\nthe Company operates. Any changes in these conditions could have an impact on\nthe guidance provided.\n\nAuna’s financial guidance reflects management’s current assumptions\nregarding numerous evolving factors that are difficult to accurately predict,\nincluding those discussed in the Risk Factors set forth in the Company’s\nForm 20-F filed with the SEC. Reconciliations of forward-looking non-IFRS\nmeasures, specifically the Leverage Ratio and Adjusted EBITDA guidance, to the\nrelevant forward-looking IFRS measures are not being provided, as the Company\ndoes not currently have sufficient data to accurately estimate the variables\nand individual adjustments for such guidance and reconciliations. Due to this\nuncertainty, the Company cannot reconcile projected Adjusted EBITDA to\nprojected net income without unreasonable effort. The financial guidance\nconstitutes forward-looking statements. For more information, see the\n“Forward-Looking Statements” section in this release.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260519356955/en/\n(https://www.businesswire.com/news/home/20260519356955/en/)\n\nIR Contact \n\nEmail: contact@aunainvestors.com (mailto:contact@aunainvestors.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-05-19T21:50:00.158869137Z","server_sent_at_ms":1779227400158},"received_at":"2026-05-19T21:50:00.316Z","source_url":"https://www.businesswire.com/news/home/20260519356955/en/"},"analysis":{"id":"29446","press_release_id":"40006","analysis_json":{"industry":{"label":"Health Care Providers & Services","sector":"Health Care"},"redFlags":["Adjusted EBITDA declined 2% YoY despite revenue growth","Net finance costs increased 76% YoY due to non-cash FX losses","Peru Adjusted EBITDA impacted by delayed pharmacy rebates and revenue adjustments","Mexico Segment Adjusted EBITDA decreased 14% YoY in local currency"],"eventType":"earnings","narrative":"Auna reported Q1 2026 revenue of S/1,178 million, up 13% year-over-year, driven by volume growth across Mexico, Peru, and Colombia.\n\nAdjusted EBITDA declined 2% YoY to S/217 million due to margin compression in Mexico and Peru, though cash flow performance was strong with FCF growing 2.6x.\n\nManagement reaffirmed full-year guidance, citing a softer first half but confidence in achieving annual targets supported by improving trends in Mexico and Colombia.","sentiment":"mixed","agentHooks":{"shouldPost":true,"suggestedAngle":"Auna Q1: Revenue growth and cash flow strength offset by EBITDA miss and FX headwinds; guidance reaffirmed."},"keyFigures":{"eps":"S/0.09","revenue":"S/1,178 million","guidance":"Reaffirmed full-year revenue and Adjusted EBITDA guidance; expects softer first half with limited growth in Q1 and Q2.","revenueYoy":"13%","customDimensions":{"net_income":"S/9 million","oncology_mlr":"49.6%","leverage_ratio":"3.7x","mexico_revenue":"S/279 million","adjusted_ebitda":"S/217 million","surgeries_count":21610,"days_hospitalized":132266,"net_finance_costs":"S/141 million","oncosalud_members":"1.4 million","free_cash_flow_yoy":"2.6x","mexico_revenue_yoy":"15%","adjusted_ebitda_yoy":"-2%","adjusted_net_income":"S/16 million","peru_revenue_lc_yoy":"9%","weighted_avg_shares":74238842,"adjusted_ebitda_margin":"18.4%","adjusted_net_income_eps":"S/0.18","colombia_revenue_lc_yoy":"14%","operating_cash_flow_yoy":"48%","mexico_segment_ebitda_qoq":"19%","colombia_segment_ebitda_yoy":"7%"}},"quotedText":"We enter the remainder of 2026 with improving trends across all three markets and a clear line of sight to achieve our annual targets.","namedEntities":{"people":[{"name":"Suso Zamora","role":"Executive Chairman and President"},{"name":"Gisele Remy","role":"Chief Financial Officer and Executive Vice President"},{"name":"Lorenzo Massart","role":"Executive Vice President of Strategy and Equity Capital Markets"}],"products":["AunaWay","Oncosalud"],"companies":[{"name":"Auna","ticker":"AUNA"},{"name":"Oncosalud","relationship":"subsidiary"},{"name":"IMAT Oncomedica","relationship":"acquisition target"}],"dollarAmounts":[{"amount":"S/1,178 million","context":"1Q26 Consolidated Revenue"},{"amount":"S/279 million","context":"1Q26 Mexico Revenue"},{"amount":"S/217 million","context":"1Q26 Adjusted EBITDA"},{"amount":"S/141 million","context":"1Q26 Net finance costs"},{"amount":"S/9 million","context":"1Q26 Net Income"},{"amount":"S/16 million","context":"1Q26 Adjusted Net Income"},{"amount":"S/0.09","context":"1Q26 Net Income per share"},{"amount":"S/0.18","context":"1Q26 Adjusted Net Income per share"},{"amount":"S/26 million","context":"Non-cash FX loss in finance costs"},{"amount":"S/37 million","context":"Non-cash FX gain in 1Q25 finance costs"}]},"materialImpact":{"score":3,"reasoning":"Revenue beat expectations with 13% YoY growth and strong cash flow (FCF up 2.6x), but Adjusted EBITDA declined 2% YoY due to margin compression and FX headwinds. Guidance was reaffirmed, not raised, reflecting a 'softer first half' outlook."},"tickerRelevance":{"others":[],"primary":"AUNA"},"globalImportance":35,"audienceRelevance":25,"eventTypeSecondary":["guidance_update"],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"earnings_beat_revenue_miss_ebitda","sectorWeight":"healthcare","householdBrandBoost":"low","marketCapAdjustment":"moderate","retailFavoriteBoost":"low"}},"event_type":"earnings","event_type_secondary":["guidance_update"],"sentiment":"mixed","material_impact_score":3,"narrative":"Auna reported Q1 2026 revenue of S/1,178 million, up 13% year-over-year, driven by volume growth across Mexico, Peru, and Colombia.\n\nAdjusted EBITDA declined 2% YoY to S/217 million due to margin compression in Mexico and Peru, though cash flow performance was strong with FCF growing 2.6x.\n\nManagement reaffirmed full-year guidance, citing a softer first half but confidence in achieving annual targets supported by improving trends in Mexico and Colombia.","key_figures":{"eps":"S/0.09","revenue":"S/1,178 million","guidance":"Reaffirmed full-year revenue and Adjusted EBITDA guidance; expects softer first half with limited growth in Q1 and Q2.","revenueYoy":"13%","customDimensions":{"net_income":"S/9 million","oncology_mlr":"49.6%","leverage_ratio":"3.7x","mexico_revenue":"S/279 million","adjusted_ebitda":"S/217 million","surgeries_count":21610,"days_hospitalized":132266,"net_finance_costs":"S/141 million","oncosalud_members":"1.4 million","free_cash_flow_yoy":"2.6x","mexico_revenue_yoy":"15%","adjusted_ebitda_yoy":"-2%","adjusted_net_income":"S/16 million","peru_revenue_lc_yoy":"9%","weighted_avg_shares":74238842,"adjusted_ebitda_margin":"18.4%","adjusted_net_income_eps":"S/0.18","colombia_revenue_lc_yoy":"14%","operating_cash_flow_yoy":"48%","mexico_segment_ebitda_qoq":"19%","colombia_segment_ebitda_yoy":"7%"}},"named_entities":{"people":[{"name":"Suso Zamora","role":"Executive Chairman and President"},{"name":"Gisele Remy","role":"Chief Financial Officer and Executive Vice President"},{"name":"Lorenzo Massart","role":"Executive Vice President of Strategy and Equity Capital Markets"}],"products":["AunaWay","Oncosalud"],"companies":[{"name":"Auna","ticker":"AUNA"},{"name":"Oncosalud","relationship":"subsidiary"},{"name":"IMAT Oncomedica","relationship":"acquisition target"}],"dollarAmounts":[{"amount":"S/1,178 million","context":"1Q26 Consolidated Revenue"},{"amount":"S/279 million","context":"1Q26 Mexico Revenue"},{"amount":"S/217 million","context":"1Q26 Adjusted EBITDA"},{"amount":"S/141 million","context":"1Q26 Net finance costs"},{"amount":"S/9 million","context":"1Q26 Net Income"},{"amount":"S/16 million","context":"1Q26 Adjusted Net Income"},{"amount":"S/0.09","context":"1Q26 Net Income per share"},{"amount":"S/0.18","context":"1Q26 Adjusted Net Income per share"},{"amount":"S/26 million","context":"Non-cash FX loss in finance costs"},{"amount":"S/37 million","context":"Non-cash FX gain in 1Q25 finance costs"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-19T21:51:03.484Z","global_importance":35,"audience_relevance":25,"importance_components":{"tickerTier":"mid-cap","eventGravity":"earnings_beat_revenue_miss_ebitda","sectorWeight":"healthcare","householdBrandBoost":"low","marketCapAdjustment":"moderate","retailFavoriteBoost":"low"}},"durationMs":63157,"modelName":"george-droid-qwen-72b"}}